Observing Quality of Life With Lutetium 177Lu Vipivotide Tetraxetan in Men With Metastatic Castration Resistant Prostate Cancer

What this Trial Is About

Researchers are studying patients with metastatic castration-resistant prostate cancer mCRPC who are starting treatment with lutetium 177Lu vipivotide tetraxetan. This observational study aims to describe routine clinical practice and the impact of this treatment on patients health-related quality of life HRQoL at various stages, including before treatment, during treatment, and after disease progression. Patients will receive lutetium 177Lu vipivotide tetraxetan in treatment cycles lasting about 6 weeks each, with up to 6 cycles total as guided by local treatment labels. Data collection points include before treatment begins if eligible, the first administration date, throughout treatment, at the end of treatment EoT, and during follow-up up to one year after the last treatment. During the study, patients will complete questionnaires to assess quality of life and pain levels, and clinical data such as progression and survival will be recorded. Researchers will monitor changes in scores from baseline through one year after treatment ends. Follow-up data collection depends on availability and may continue for up to a year post-treatment. The study is sponsored by Novartis Pharmaceuticals and focuses on real-world patient experiences.

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer